Effect of Photobiomodulation in Patients With Temporomandibular Dysfunction Refractory to Botulinum Toxin Treatment.
Launched by UNIVERSITY OF COIMBRA · Apr 3, 2025
Trial Information
Current as of May 25, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Female patients diagnosed with TMDs. Presence of unilateral or bilateral painful symptoms. Associated conditions: Bruxism, hypertrophy of the masticatory muscles, headaches
- * Previous treatment with BTX:
- • Minimum of 3 doses (100 IU) Applied in masticatory muscles and intracapsular area No favorable results obtained
- Exclusion Criteria:
- • Patients without prior treatment of this type.
- • Patients receiving treatment in the Pain Unit.
- • Patients undergoing invasive treatments: Open surgery in the cervicofacial region or TMJ arthrocentesis.
About University Of Coimbra
The University of Coimbra, a prestigious institution in Portugal, is dedicated to advancing medical research and innovation through its clinical trial initiatives. With a strong emphasis on collaborative research and interdisciplinary approaches, the university fosters a robust environment for the development of cutting-edge therapies and interventions. Its clinical trials aim to address critical health challenges, leveraging the expertise of its distinguished faculty and state-of-the-art facilities. Committed to ethical standards and patient welfare, the University of Coimbra plays a pivotal role in translating scientific discoveries into tangible health solutions, contributing to the global body of medical knowledge.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Salamanca, , Spain
Patients applied
Trial Officials
Nanci Lopez-Valverde, PhD
Principal Investigator
University of Salamanca
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported